Status:
UNKNOWN
The Population Pharmacokinetics Study of Tigecycline and Pharmacokinetics- Pharmacodynamics Index in Patients With Carbapenem Resistant Enterobacteriaceae Bloodstream Infection
Lead Sponsor:
Phramongkutklao College of Medicine and Hospital
Collaborating Sponsors:
Silpakorn University
Conditions:
Carbapenem-resistant Enterobacteriaceae
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent global public health problem. Patients who were infected caused by CRE bloodstream infection were high mortality up to 40%. The National Ant...
Detailed Description
Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent global public health problem. Patients who were infected caused by CRE bloodstream infection were high mortality up to 40%. The National Ant...
Eligibility Criteria
Inclusion
- 20 years and older who were admitted at Phramongkutklao Hospital
- Patients who were diagnosed bloodstream infection with CRE and who were sepsis or septic shock
- Patients who received tigecycline loading dose 200 mg infusion for 1 hour and following maintenance dose 100 mg every 12 h infusion for 1 hour at least 48 hours and grant for blood collection
Exclusion
- Pregnancy or Breastfeeding
- Patients who cannot tolerant to the toxicity of tigecycline for example hypersensitivity to tigecycline or any component of the formulation
- Patients who were infected with more than one isolated in blood culture at the same time
Key Trial Info
Start Date :
September 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT06049771
Start Date
September 17 2023
End Date
June 30 2025
Last Update
September 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Phramongkutklao Hospital
Ratchathewi, Bangkok, Thailand, 10400